UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of October 2025
Commission
File Number: 001-41677
CytoMed
Therapeutics Limited
(Exact
name of registrant as specified in its charter)
1
Commonwealth Lane
#08-22
Singapore
149544
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
INFORMATION
CONTAINED IN THIS FORM 6-K REPORT
On
October 2, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing a publication based on collaborative
research with The University of Texas, MD Anderson Cancer Center, which demonstrates the potential of the Company’s Allogeneic
γδ T Cells to treat Acute Myeloid Leukemia.
A
copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.
Exhibits
| Exhibit
No. |
|
Description |
| |
|
|
| 99.1 |
|
Press Release dated October 2, 2025, titled: CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia |
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
| |
CytoMed
Therapeutics Limited |
| |
|
|
| |
By: |
/s/
CHOO Chee Kong |
| |
Name: |
CHOO
Chee Kong |
| Date:
October 2, 2025 |
Title: |
Director
and Chairman |
